Indonesia, June 17 -- Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited ("Dimerix"), for the development and commercialization of DMX-200 in Greater China (Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan region), South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines). This collaboration will further strengthen Everest's nephrology product portfolio and pipeline synergy, reinforce the company's strategic position in kidney and autoimmune diseases.

Under the terms of the agreement, Everest will pay Dimerix a US$ 10 million upfront payment, and up to US$30 million potential success-based devel...